EZH2 overexpression has been reported to be related with increased tumor cell proliferation and worse outcome in several carcinomas including breast cancer [14], endometrial carcinomas [15] and hormone-refractory prostate cancer [16], which indicated that the expression of EZH2 protein might serve as the potential biomarker in carcinomas. Here, EZH2 is linked to neoplasm.